Dossier assessment

Bimekizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V

Report documents

Indication:

Adult patients with moderate to severe plaque psoriasis

Result of dossier assessment:

Patients who are not candidates for conventional treatment in the framework of an initial systemic therapy: hint of minor added benefit.
Patients who have had an inadequate response or who have been intolerant to systemic therapy: added benefit not proven.

Federal Joint Committee (G-BA)

2022-03-03 A G-BA decision was published.

Project no.: A21-110
Commission: Commission awarded on 15.09.2021 by the Federal Joint Committee (GBA).
Report type: Dossier assessment
Status: Commission completed
Department/Division: Drug Assessment
Topic: Skin and hair
Note: After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

The current version 1.1 of the dossier assessment replaces version 1.0 published on 2021-12-15.

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.